Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03376841 · ClinicalTrials.gov registry record · Phase 1
Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03376841 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 16 participants.
The verdict
NCT03376841, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability profiles of cenicriviroc (CVC) and its metabolites (M-I and M-II) in participants with severely impaired hepatic function compared with matched healthy participants following single-dose administration
Interventions
- DRUG Cenicriviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2017-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03376841
The ClinicalTrials.gov registry entry for NCT03376841 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cenicriviroc is the first listed.
NCT03376841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03376841 about?
NCT03376841 is a clinical study titled "Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites". The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability profiles of cenicriviroc (CVC) and its metabolites (M-I and M-II) in participants with severely impaired hepatic function compared with matched healthy participants following single-dose administration
What is the current status of trial NCT03376841?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-06-06. Estimated completion is 2017-12-17.
What interventions are being tested in trial NCT03376841?
The interventions under investigation include: Cenicriviroc (DRUG).
Who is sponsoring clinical trial NCT03376841?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.